About this trial
Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies. The adverse outcomes extend beyond maternal well-being to long-term deficits in children and families. The gut-brain axis is a newly recognized key player in mental health disorders. Specifically, the microbial composition of the gut along with their metabolites are directly involved in disease onset and course. Recent clinical studies have identified diet as the most powerful environmental factor in manipulating gut microbiome. Given vulnerability and resistance of pregnant women to pharmacotherapy, particularly in those with a predisposition to mood disorders, as well as pregnant women's high motivation and commitment to improving gestational diet, a dietary/supplemental intervention to 'optimize' gut microbiome, is a favored approach in disease management. The study investigators aim to exploit microbial responsiveness to diet together with this maternal motivation, to alter the risk and severity of a universal public health concern that has dire and long-term consequences for new moms and their children.
The investigators of this trial, will first study the challenges in pursuing a study aimed at changing the microbiome of pregnant women with a history of mood disorders. Pregnant women in their second trimester will be recruited. Each will be assigned or randomized to one of four groups that will use a combination of diet, supplementation with probiotics, fish oil or no intervention. Each participant will meet with the study team virtually every 3 months until 1 year after delivery. At each study visit participants will be required to complete some questionnaires about their food intake, mood, and other health related measures and will provide a stool sample using the stool collection kits provided.
The findings from this study will help strategize for a larger study that will allow for comparison of the effects of diet, and/or supplementation with Omega-3 Fatty Acids (O3FA) and probiotics on the microbiome and the onset and severity of PDA.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Women 18-43 years old
12-35 weeks of gestation
Non-smoker/alcohol/recreational drug user
Financially stable
Disqualifiers
Body Mass Index (BMI)≥30
Low income (unable to afford basic daily needs (i.e., shelter, food, etc.)
Diagnosis with other major mental health disorders (Bipolar, Psychosis, Addiction, Schizophrenia);
Diagnosis with other severe medical conditions (i.e. epilepsy, neurological disorders, etc.)
Trial design
Parallel
Treatments tested in this trial
Fish oil
Dietary supplement1500mg EPA +1000mg DHA daily
Probiotics
Dietary supplementCombination strain of lactobacillus and bifidobacteria
Prebiotics
BehavioralDietary consult with follow-up to ensure target fiber intake is met.
Diet Quality
Behavioralone time dietary consult at enrollment to discuss strategies to improve overall diet.
Treatment groups
Trial outcomes
Primary outcomes
Feasibility of participant recruitment
Time taken to recruit 100 participants in total and successfully randomize/assign 25 participants per study arm.
Adherence to Supplement Intake (estimated using unused portion of supplements)
This outcome will be measured by participants' adherence to the prescribed regiments. At each visit the between-study-visit intake of fish oil, probiotics/ placebo will be estimated by what remains unused in the original boxes/containers
Adherence to Supplement Intake (Number of missed doses/week)
Questionnaires detailing intake frequency of the supplements and missed doses will be used in Groups A, B \& C, to assess adherence to prescribed regiments
Adherence to Dietary Protocol (Using food frequency questionnaire)
Adherence to the dietary protocol in Group A, will be measured at each study visit and in between study visits to ensure the dietary target is met (i.e. the number of daily servings of specific foods are consumed), and to address and document challenges in reaching the targets.
Secondary outcomes
Study Obstacles (descriptive measures outlining obstacles)
The actual rate of recruitment, intervention acceptability, completion of study tasks (Dietary intake, EPDS, GAD6, stool collection, lifestyle questionnaires), study visit (\<6 visits) will be compared to the expected rates at the time of study design. All obstacles to attaining the expected rate, will be documented with descriptive measures.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
The Canadian College of Naturopathic Medicine
Lead sponsor
Sunnybrook Health Sciences Centre
Collaborator
Lotte & John Hecht Memorial Foundation
Collaborator